We are pleased to present the exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer. This series provides peer-to-peer physician perspectives on emerging data in the treatment of hormone receptor (HR)-positive/HER2-negative early to metastatic breast cancer. Sponsored by Lilly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Claim This Podcastby Amplity, Inc.
6 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇺🇸
Podcast Overview
We are pleased to present the exclusive podcast series, Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer. This series provides peer-to-peer physician perspectives on emerging data in the treatment of hormone receptor (HR)-positive/HER2-negative early to metastatic breast cancer. Sponsored by Lilly
Language
🇺🇲
Publishing Since
1/14/2026
Reach the team behind Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Verified contact details for this show aren't on file yet — sign up to get notified when they land.
Recent Episodes
February 17, 2026
Part 6: Results From OptiTROP-Breast02
<p>We are pleased to present <strong>Part 6</strong>, the final installment of an exclusive podcast series, <strong>Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer</strong>.</p><p>Part 6 of this series provides peer-to-peer physician perspectives on the results from the OptiTROP-Breast02 trial.</p><p><strong>Topics include:</strong></p><ol><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>Results from OptiTROP-Breast02: Sacituzumab tirumotecan (sac-TMT) as a novel TROP2-directed antibody drug conjugate (ADC)</li><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>Future direction of ADC treatments</li></ol><br/><p><strong>Discussants:</strong></p><p><strong>Neil M. Iyengar, MD</strong></p><p>Director, Survivorship Services, Winship Cancer Institute of Emory University</p><p>Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology</p><p>Associate Professor, Department of Hematology and Medical Oncology</p><p>Emory University School of Medicine</p><p>Atlanta, GA</p><p><strong>Seth Wander, MD, PhD</strong></p><p>Director, Precision Medicine, Termeer Center for Targeted Therapies</p><p>Director, Translational Research, Breast Oncology Program</p><p>Assistant Professor of Medicine, Harvard Medical School</p><p>Massachusetts General Hospital</p><p>Boston, MA</p><p><strong>Sponsored by <a href="https://www.lilly.com/" rel="noopener noreferrer" target="_blank">Lilly</a></strong></p>
February 10, 2026
Part 5: Results From TACTIVE-N
<p>We are pleased to present <strong>Part 5</strong> of an exclusive podcast series, <strong>Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer</strong>.</p><p>Part 5 of this series provides peer-to-peer physician perspectives on the results from the TACTIVE-N trial.</p><p><strong>Topics include:</strong></p><ol><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>Neoadjuvant vepdegestrant: results of TACTIVE-N trial</li><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>Tolerance in next-generation endocrine therapies: PROTAC estrogen receptor degraders</li></ol><br/><p><strong>Discussants:</strong></p><p><strong>Neil M. Iyengar, MD</strong></p><p>Director, Survivorship Services, Winship Cancer Institute of Emory University</p><p>Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology</p><p>Associate Professor, Department of Hematology and Medical Oncology</p><p>Emory University School of Medicine</p><p>Atlanta, GA</p><p><strong>Seth Wander, MD, PhD</strong></p><p>Director, Precision Medicine, Termeer Center for Targeted Therapies</p><p>Director, Translational Research, Breast Oncology Program</p><p>Assistant Professor of Medicine, Harvard Medical School</p><p>Massachusetts General Hospital</p><p>Boston, MA</p><p><strong>Sponsored by <a href="https://www.lilly.com/" rel="noopener noreferrer" target="_blank">Lilly</a></strong></p>
February 4, 2026
Part 4: First Results From VIKTORIA-1
<p>We are pleased to present <strong>Part 4</strong> of an exclusive podcast series, <strong>Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer</strong>.</p><p>Part 4 of this series provides peer-to-peer physician perspectives on the first results from the VIKTORIA-1 trial.</p><p><strong>Topics include:</strong></p><ol><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>Mechanisms of resistance to CDK4/6 inhibitors</li><li data-list="bullet"><span class="ql-ui" contenteditable="false"></span>Rationale, design, and results of VIKTORIA-1 for the PIK3CA, wild-type cohort</li></ol><br/><p><strong>Discussants:</strong></p><p><strong>Neil M. Iyengar, MD</strong></p><p>Director, Survivorship Services, Winship Cancer Institute of Emory University</p><p>Co-Director, Breast Medical Oncology, Department of Hematology and Medical Oncology</p><p>Associate Professor, Department of Hematology and Medical Oncology</p><p>Emory University School of Medicine</p><p>Atlanta, GA</p><p><strong>Seth Wander, MD, PhD</strong></p><p>Director, Precision Medicine, Termeer Center for Targeted Therapies</p><p>Director, Translational Research, Breast Oncology Program</p><p>Assistant Professor of Medicine, Harvard Medical School</p><p>Massachusetts General Hospital</p><p>Boston, MA</p><p><strong>Sponsored by <a href="https://www.lilly.com/" rel="noopener noreferrer" target="_blank">Lilly</a></strong></p>
6 total episodes available
Similar Podcasts
Discover related shows you might enjoy
Deep-dive analytics for Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.